GO:0007208 phospholipase C-activating serotonin receptor signaling pathway

GO:0007208, phospholipase C-activating serotonin receptor signaling pathway, is a biological process that describes how serotonin binding to its receptor on the cell surface triggers a G protein-coupled signaling cascade culminating in phospholipase C activation and regulation of downstream cellular responses. This term captures a specific mode of serotonin receptor signaling that is distinct from pathways that modulate adenylyl cyclase or ion channels, and it is central to understanding how serotonergic neurotransmission is translated into cellular changes. Because serotonin receptors are major targets of antipsychotic, antidepressant, and antiemetic drugs, the PLC-activating branch of serotonin signaling is of broad pharmacological and clinical interest. Mechanistically, the pathway begins when serotonin (5-HT) binds to a Gq/11-coupled serotonin receptor, promoting GDP-GTP exchange on the G alpha subunit and activation of phospholipase C beta enzymes. Active PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium and activate protein kinase C, respectively. These second messengers propagate the signal to downstream effectors, including transcription factors, thereby shaping neuronal excitability, plasticity, and gene expression. For researchers, GO:0007208 provides a precise annotation framework for experiments that interrogate serotonin receptor coupling to PLC, including studies of receptor subtype specificity, G protein selectivity, and drug pharmacology. The term is also useful in systems pharmacology and network pharmacology analyses that map drug mechanisms onto signaling pathways, as illustrated by studies of aripiprazole in hyperprolactinemia. Understanding this pathway at the molecular level supports the development of targeted therapies for psychiatric and neurological disorders.

GO:0007208 is defined as a phospholipase C-activating receptor G protein-coupled receptor signaling pathway initiated by serotonin binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, such as transcription. In simpler terms, it is the sequence of molecular events through which serotonin, acting at a specific class of receptors, turns on phospholipase C and thereby changes what the cell does.

GO:0007208 is important because it defines one of the principal signaling routes by which serotonin, a neurotransmitter and peripheral hormone, controls cell behavior. Serotonin receptors that activate phospholipase C are expressed in the brain, vasculature, gastrointestinal tract, and other tissues, and they are targets of widely prescribed drugs including atypical antipsychotics and antidepressants. By providing a standardized annotation for this pathway, GO:0007208 enables researchers to compare experimental results across studies, interpret drug mechanisms, and build computational models of serotonergic signaling in health and disease.

The following genes and proteins are central to the phospholipase C-activating serotonin receptor signaling pathway, based on published pharmacological and signaling studies.

The phospholipase C-activating serotonin receptor signaling pathway is regulated at multiple levels, including receptor desensitization by G protein-coupled receptor kinases and beta-arrestins, which uncouple the receptor from Gq/11 and terminate PLC activation. Phospholipase C activity itself can be modulated by calcium and by phosphorylation, providing feedback control of IP3 and DAG production. Additionally, the pathway intersects with other signaling cascades, such as those involving protein kinase C-mediated negative feedback, which can dampen receptor signaling. In pharmacological contexts, drugs such as aripiprazole can modulate serotonergic signaling, as suggested by network pharmacology analyses.

Serotonin receptors that activate phospholipase C, particularly HTR2A and HTR2C, are major targets of atypical antipsychotic drugs used to treat schizophrenia and related disorders. Network pharmacology and molecular docking studies of aripiprazole have implicated PLC-activating serotonin receptor signaling in its pharmacological mechanism, including effects on prolactin regulation. Dysregulation of serotonergic signaling has been associated with mood disorders, anxiety, and psychosis, making this pathway a focus of neuropsychopharmacology research.

Aripiprazole, an antipsychotic with partial agonist activity at serotonin and dopamine receptors, is used to manage hyperprolactinemia, and computational studies suggest that modulation of serotonergic pathways, including PLC-activating signaling, contributes to its effects. This illustrates how GO:0007208 can be relevant to endocrine side effects of psychiatric medications.

HTR2B, a Gq/11-coupled serotonin receptor that activates PLC, has been implicated in cardiac valve disease and pulmonary hypertension associated with serotonergic drugs. Understanding the PLC-activating branch of serotonin signaling is therefore important for assessing drug safety in peripheral tissues.

Because the pathway generates IP3 and mobilizes intracellular calcium, calcium imaging with fluorescent indicators and IP3 competition assays are standard methods to measure pathway activity. These approaches can be applied to wild-type and CRISPR-modified cells to test the contribution of specific receptors or PLC isoforms.

Measuring the hydrolysis of PIP2 or the accumulation of inositol phosphates provides a direct readout of phospholipase C activity downstream of serotonin receptor activation. Such assays are useful for quantifying agonist efficacy and drug effects on the pathway.

RNA sequencing and network pharmacology analyses can identify transcriptional changes and pathway enrichment associated with PLC-activating serotonin receptor signaling. These methods help link the pathway to drug mechanisms and disease phenotypes.

Molecular docking and computational modeling are used to predict how drugs such as aripiprazole interact with serotonin receptors and other pathway components. These in silico approaches complement experimental validation of pathway modulation.

Researchers studying phospholipase C-activating serotonin receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in serotonin-stimulated PLC activation or in downstream transcriptional responses. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to support such investigations, from gene knockout to precise point mutations and knock-in reporters.

GO:0007208 provides a precise annotation for the serotonin-stimulated, phospholipase C-dependent signaling pathway that links neurotransmitter binding to calcium signaling, PKC activation, and transcriptional regulation. This pathway is central to neuropsychopharmacology and has been implicated in the mechanisms of antipsychotic drugs such as aripiprazole. Continued research using CRISPR-based cell models and multi-omics approaches will further clarify how this pathway contributes to health and disease.